
Zentalis Pharmaceuticals, Inc.: shareholders and insiders
Price
$1.36
November 20, 2026Market cap $134M
What Ploutos Investor adds for Zentalis Pharmaceuticals
Part of Ploutos Investor, €9.99 a month
- The full history: 4 fiscal years, from 2022
- The estimated fair value, with its range and its certainty
- The full analysis, 18 a month
- More questions to the chat on its filings
- Excel with every year
- An email when it reports, changes its dividend or an officer buys
Sign in with a free account to see the last 5 fiscal years.
Notes on these figures
- The share price has fallen 22% since Nov 9, 2026, when the 10-Q these figures come from was filed ($1.74 then, $1.36 on Nov 20, 2026). The figures date from before that move.10-Q
Insiders and their shares
Purchases and sales by officers and directors from Nov 22, 2025 to Oct 1, 2026, from their own Form 4 filings.
Bought on the market
$23M
2 people
Sold on the market
$10M
4 people
From Nov 22, 2025 to Nov 22, 2026, the days the chart shows. Change its range and the figures follow.
How the sales were made, as a share of their value
- Under a set plan1%
- The rest99%
By year
Insiders' open-market purchases (up) and sales (down), by value, since Nov 22, 2025, on a log scale: each gridline is ten times the last. From the SEC's quarterly data sets of Form 4 filings.
2026·bought $15M by 1 person·sold $134.7K by 3 people
- 2025: bought $7.8M by 1 person, sold $10.0M by 1 person
- 2026: bought $15M by 1 person, sold $134.7K by 3 people
- Sep 30, 2026Ingmar BrunsChief Medical OfficerKind
- Aug 14, 2026Walters GroupKind
- Jun 16, 2026David Michael JohnsonDirectorKind
- Jun 16, 2026Jan SkvarkaDirectorKind
- Jun 16, 2026Luke Nathaniel WalkerDirectorKind
- Jun 16, 2026Enoch KariukiDirectorKind
- Jun 16, 2026Scott Dunseth MyersDirectorKind
- May 26, 2026Shannon CampbellDirectorKind
- Feb 10, 2026Vincent VultaggioPAO and PFOKind10b5-1
- Feb 9, 2026Julia Marie EastlandCEO & PresidentKind
- Feb 9, 2026Ingmar BrunsChief Medical OfficerKind
- Feb 9, 2026Vincent VultaggioPAO and PFOKind10b5-1
- Feb 6, 2026Julia Marie EastlandCEO & PresidentKind
- Feb 6, 2026Ingmar BrunsChief Medical OfficerKind
- Feb 6, 2026Vincent VultaggioPAO and PFOKind10b5-1
- Feb 3, 2026Vincent VultaggioPAO and PFOKind10b5-1
- Feb 2, 2026Vincent VultaggioPAO and PFOKind10b5-1
| Date | Person | Kind | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| Sep 30, 2026 | Ingmar BrunsChief Medical Officer | 9,727 | $2.18 | $21.2K | Form 4 | |
| Aug 14, 2026 | Walters Group | 4.34M | $3.50 | $15M | Form 4 | |
| Jun 16, 2026 | David Michael JohnsonDirector | 57.1K | – | – | Form 4 | |
| Jun 16, 2026 | Jan SkvarkaDirector | 57.1K | – | – | Form 4 | |
| Jun 16, 2026 | Luke Nathaniel WalkerDirector | 57.1K | – | – | Form 4 | |
| Jun 16, 2026 | Enoch KariukiDirector | 57.1K | – | – | Form 4 | |
| Jun 16, 2026 | Scott Dunseth MyersDirector | 57.1K | – | – | Form 4 | |
| May 26, 2026 | Shannon CampbellDirector | 114.2K | – | – | Form 4 | |
| Feb 10, 2026 | Vincent VultaggioPAO and PFO | 10b5-1 | 6,894 | $2.42 | $16.7K | Form 4 |
| Feb 9, 2026 | Julia Marie EastlandCEO & President | 889 | $2.39 | $2.1K | Form 4 | |
| Feb 9, 2026 | Ingmar BrunsChief Medical Officer | 335 | $2.39 | $801 | Form 4 | |
| Feb 9, 2026 | Vincent VultaggioPAO and PFO | 10b5-1 | 3,379 | $2.39 | $8.1K | Form 4 |
| Feb 6, 2026 | Julia Marie EastlandCEO & President | 7,866 | $2.43 | $19.1K | Form 4 | |
| Feb 6, 2026 | Ingmar BrunsChief Medical Officer | 2,962 | $2.43 | $7.2K | Form 4 | |
| Feb 6, 2026 | Vincent VultaggioPAO and PFO | 10b5-1 | 30.0K | $2.43 | $72.8K | Form 4 |
| Feb 3, 2026 | Vincent VultaggioPAO and PFO | 10b5-1 | 556 | $2.52 | $1.4K | Form 4 |
| Feb 2, 2026 | Vincent VultaggioPAO and PFO | 10b5-1 | 2,540 | $2.55 | $6.5K | Form 4 |
From the Form 4s insiders file with the SEC within two business days of each trade. Before May 27, 2026 the table lists open-market purchases and sales only (no grants, option exercises or tax withholding), from the SEC's quarterly data sets. The 10b5-1 mark comes from the form's own box (since April 2023) or from a footnote of the filing that names the plan, where there is one.
Insiders and their shares
Every buy and sale by ZNTL's officers and directors from 2020 up to November 21, 2025, 6 more calendar years
Part of Ploutos Investor, €9.99 a month
Sign in with a free account to see the last 3 years.
and 1 more, back to 2020
Major holders (over 5%)
Whoever comes to own more than 5% of a class of shares reports it to the SEC on Schedule 13D or 13G. Here is each holder's latest filing.
- Walters William Twith 2 more personsShare of class18.8%
- 5AM Opportunities II (GP), LLCwith 6 more personsShare of class6.40%
- Squadron Master Fund LPwith 3 more personsShare of class5.10%
| Holder | Kind of stake | Share of class | Shares | Filed | Filing |
|---|---|---|---|---|---|
| Walters William Twith 2 more persons | 18.8% | 17.84M | Aug 19, 20266 filings since Dec 10, 2024 | 13G/A | |
| 5AM Opportunities II (GP), LLCwith 6 more persons | 6.40% | 4.84M | Dec 30, 2025 | 13G | |
| Squadron Master Fund LPwith 3 more persons | 5.10% | 3.68M | Mar 3, 2026 | 13G |
Fell to 5% or less (7)
Holders whose latest filing says they hold 5% or less. After it they need not file again, so what they hold today is not known.
From the Schedule 13D and 13G filed with the SEC since Dec 18, 2024, when they became structured data. A holder who has filed nothing since then is not shown here. A 13D is updated within two business days of any material change, a 13G up to 45 days after the quarter of the change, so the shares are those of the filing. The large managers also appear in the 13Fs.
Well-known managers
Which of the about 30 investment managers we track held the shares at the quarter end, and what they changed from the quarter before.
- Citadel Advisors (Griffin)In the quarter+95%
- Renaissance TechnologiesIn the quarter-6.9%
- Millennium Mgmt (Englander)In the quarter-28%
- D.E. ShawIn the quarter-51%
- AQR CapitalIn the quarter
| Manager | Shares | In the quarter | Value | % of their portfolio |
|---|---|---|---|---|
| Citadel Advisors (Griffin) | 4.49M | +95% | $12M | 0.01% |
| Renaissance Technologies | 1.50M | -6.9% | $4.2M | 0.01% |
| Millennium Mgmt (Englander) | 477.8K | -28% | $1.3M | 0.00% |
| D.E. Shaw | 269.6K | -51% | $700.0K | 0.00% |
| AQR Capital | 446.8K | $1.2M | 0.00% |
From the 13Fs managers file with the SEC up to 45 days after each quarter end. They show only long positions on that day, not short sales or what has changed since. No recent 13F: Pershing Square (Ackman), Scion (Burry).
Short interest
How many of the company's shares have been sold borrowed and not yet bought back, twice a month.
On Oct 15, 2026, 6.09% of its shares outstanding were held short, +0.5% since the report before.
- Shares held short
- 5.99M
- 6.09%
- Since the report before5.96M on Sep 30, 2026
- +0.5%
- 4.8
- 1.25M
- More days to cover thanof 4,578 US-listed companies with enough volume
- 59%
- Report date
- Oct 15, 2026
- Shares held short
- Oct 31, 2023: Shares held short 11.14M
- Nov 15, 2023: Shares held short 10.58M
- Nov 30, 2023: Shares held short 11.09M
- Dec 15, 2023: Shares held short 11.59M
- Dec 29, 2023: Shares held short 12.75M
- Jan 12, 2024: Shares held short 13.07M
- Jan 31, 2024: Shares held short 13.67M
- Feb 15, 2024: Shares held short 14.33M
- Feb 29, 2024: Shares held short 14.56M
- Mar 15, 2024: Shares held short 16.74M
- Mar 28, 2024: Shares held short 15.53M
- Apr 15, 2024: Shares held short 16.64M
- Apr 30, 2024: Shares held short 17.50M
- May 15, 2024: Shares held short 18.53M
- May 31, 2024: Shares held short 17.51M
- Jun 14, 2024: Shares held short 17.84M
- Jun 28, 2024: Shares held short 9.62M
- Jul 15, 2024: Shares held short 10.42M
- Jul 31, 2024: Shares held short 11.31M
- Aug 15, 2024: Shares held short 11.57M
- Aug 30, 2024: Shares held short 12.28M
- Sep 13, 2024: Shares held short 11.70M
- Sep 30, 2024: Shares held short 8.64M
- Oct 15, 2024: Shares held short 7.66M
- Oct 31, 2024: Shares held short 7.05M
- Nov 15, 2024: Shares held short 4.97M
- Nov 29, 2024: Shares held short 4.67M
- Dec 13, 2024: Shares held short 5.50M
- Dec 31, 2024: Shares held short 4.54M
- Jan 15, 2025: Shares held short 5.08M
- Jan 31, 2025: Shares held short 4.85M
- Feb 14, 2025: Shares held short 5.19M
- Feb 28, 2025: Shares held short 5.17M
- Mar 14, 2025: Shares held short 5.33M
- Mar 31, 2025: Shares held short 4.77M
- Apr 15, 2025: Shares held short 5.27M
- Apr 30, 2025: Shares held short 5.82M
- May 15, 2025: Shares held short 6.17M
- May 30, 2025: Shares held short 5.88M
- Jun 13, 2025: Shares held short 5.70M
- Jun 30, 2025: Shares held short 5.07M
- Jul 15, 2025: Shares held short 4.77M
- Jul 31, 2025: Shares held short 4.71M
- Aug 15, 2025: Shares held short 4.46M
- Aug 29, 2025: Shares held short 4.48M
- Sep 15, 2025: Shares held short 4.54M
- Sep 30, 2025: Shares held short 4.42M
- Oct 15, 2025: Shares held short 4.94M
- Oct 31, 2025: Shares held short 4.99M
- Nov 14, 2025: Shares held short 5.08M
- Nov 28, 2025: Shares held short 5.13M
- Dec 15, 2025: Shares held short 5.50M
- Dec 31, 2025: Shares held short 4.11M
- Jan 15, 2026: Shares held short 4.83M
- Jan 30, 2026: Shares held short 4.03M
- Feb 13, 2026: Shares held short 3.78M
- Feb 27, 2026: Shares held short 3.78M
- Mar 13, 2026: Shares held short 4.17M
- Mar 31, 2026: Shares held short 4.26M
- Apr 15, 2026: Shares held short 5.20M
- Apr 30, 2026: Shares held short 5.49M
- May 15, 2026: Shares held short 4.92M
- May 29, 2026: Shares held short 5.02M
- Jun 15, 2026: Shares held short 4.98M
- Jun 30, 2026: Shares held short 5.87M
- Jul 15, 2026: Shares held short 6.15M
- Jul 31, 2026: Shares held short 5.58M
- Aug 14, 2026: Shares held short 5.97M
- Aug 31, 2026: Shares held short 4.99M
- Sep 15, 2026: Shares held short 4.79M
- Sep 30, 2026: Shares held short 5.96M
- Oct 15, 2026: Shares held short 5.99M
As brokers report them to the regulator twice a month, mid-month and at month end, published about eight business days later. A short position is shares sold borrowed and not yet bought back. The share count is the one the company's market value is figured on, from its filings. Days to cover is the shares held short over the average daily volume of the weeks between two reports.
Short sales in daily trading35.3% of the shares in the last 14 sessions' reported trades were short sales.
In the last 14 sessions, 35.3% of the shares in the reported trades were short sales, against 47.2% in the 14 before.
- Last 14 sessionsNov 3, 2026 – Nov 20, 2026
- 35.3%
- The 14 beforeOct 14, 2026 – Nov 2, 2026
- 47.2%
- Change
- -11.9 pts
- Short sales a dayon average, of 619.1K shares
- 218.3K
- More than atof 3,666 US-listed companies, same days
- 11%
- Median of alleight in ten from 34.4% to 63.9%
- 50.5%
- Short sales
- Oct 14, 2026: Short sales 31.8%
- Oct 15, 2026: Short sales 13.6%
- Oct 16, 2026: Short sales 39.7%
- Oct 19, 2026: Short sales 79.4%
- Oct 20, 2026: Short sales 45.7%
- Oct 21, 2026: Short sales 38.1%
- Oct 22, 2026: Short sales 52.3%
- Oct 23, 2026: Short sales 61.7%
- Oct 26, 2026: Short sales 52.1%
- Oct 27, 2026: Short sales 35.5%
- Oct 28, 2026: Short sales 60.1%
- Oct 29, 2026: Short sales 51.1%
- Oct 30, 2026: Short sales 58.7%
- Nov 2, 2026: Short sales 41.3%
- Nov 3, 2026: Short sales 46.9%
- Nov 4, 2026: Short sales 33.1%
- Nov 5, 2026: Short sales 47.8%
- Nov 6, 2026: Short sales 22.8%
- Nov 9, 2026: Short sales 39.3%
- Nov 10, 2026: Short sales 25.8%
- Nov 11, 2026: Short sales 26.6%
- Nov 12, 2026: Short sales 34.5%
- Nov 13, 2026: Short sales 17%
- Nov 16, 2026: Short sales 33%
- Nov 17, 2026: Short sales 39.9%
- Nov 18, 2026: Short sales 38.4%
- Nov 19, 2026: Short sales 53.4%
- Nov 20, 2026: Short sales 46.4%
This is not the number of shares sold short today: it measures short sales within each day's trading, and only trades made off the exchanges. Much of it is market makers, who sell shares they do not have to fill buyers' orders and cover soon after, so for a heavily traded stock the share is often around half.
What the insiders hold
The shares each insider reports holding after their latest trade (Form 4), for those who traded on the market in the last three years.
- William Thurman WaltersTenPercentOwnerDirectly17.84M
- Walters GroupDirectly17.84M
- David E. GoelTenPercentOwnerDirectly–
- Andrea PaulChief Legal OfficerDirectly1.07M
- Cam GallagherPresident, Interim CFODirectly633.7K
- Mark LacknerChief Scientific OfficerDirectly512.9K
- Epperly Melissa B,Chief Financial OfficerDirectly451.4K
- Scott Dunseth MyersDirectorDirectly395.9K
- Diana HausmanChief Medical OfficerDirectly373.9K
- David Michael JohnsonDirectorDirectly307.5K
- Jan SkvarkaDirectorDirectly264.3K
- Luke Nathaniel WalkerDirectorDirectly201.4K
- Enoch KariukiDirectorDirectly194.5K
- Vincent VultaggioPAO and PFODirectly146.5K
- Shannon CampbellDirectorDirectly114.2K
- Julia Marie EastlandCEO & PresidentDirectly79.1K
- Ingmar BrunsChief Medical OfficerDirectly43.1K
| Person | Directly | Indirectly | After the trade of | Filing |
|---|---|---|---|---|
| William Thurman WaltersTenPercentOwner | 17.84M | – | Aug 14, 2026 | Form 4 |
| Walters Group | 17.84M | – | Aug 14, 2026 | Form 4 |
| David E. GoelTenPercentOwner | – | 6.46M | Dec 15, 2025 | Form 4 |
| Andrea PaulChief Legal Officer | 1.07M | – | Feb 3, 2025 | Form 4 |
| Cam GallagherPresident, Interim CFO | 633.7K | – | May 31, 2024 | Form 4 |
| Mark LacknerChief Scientific Officer | 512.9K | – | Feb 3, 2025 | Form 4 |
| Epperly Melissa B,Chief Financial Officer | 451.4K | – | Feb 12, 2024 | Form 4 |
| Scott Dunseth MyersDirector | 395.9K | – | Jun 16, 2026 | Form 4 |
| Diana HausmanChief Medical Officer | 373.9K | – | May 9, 2024 | Form 4 |
| David Michael JohnsonDirector | 307.5K | – | Jun 16, 2026 | Form 4 |
| Jan SkvarkaDirector | 264.3K | – | Jun 16, 2026 | Form 4 |
| Luke Nathaniel WalkerDirector | 201.4K | – | Jun 16, 2026 | Form 4 |
| Enoch KariukiDirector | 194.5K | – | Jun 16, 2026 | Form 4 |
| Vincent VultaggioPAO and PFO | 146.5K | – | Feb 10, 2026 | Form 4 |
| Shannon CampbellDirector | 114.2K | – | May 26, 2026 | Form 4 |
| Julia Marie EastlandCEO & President | 79.1K | – | Feb 9, 2026 | Form 4 |
| Ingmar BrunsChief Medical Officer | 43.1K | – | Sep 30, 2026 | Form 4 |
A lower bound: it counts only the 17 officers and directors with a market trade since Nov 23, 2023. Anyone who neither bought nor sold since is not here, whatever they hold. The share is against the share count on the latest 10-K's cover.
The ETFs that hold it
Which of the 349 US equity ETFs we track hold the stock, and at what weight, from the funds' N-PORT filings.
- IWCiShares Micro-Cap ETFWeight in the fund0.05%
- FESMFidelity Enhanced Small Cap Core ETFWeight in the fund0.02%
- IWNiShares Russell 2000 Value ETFWeight in the fund0.02%
- IWMiShares Russell 2000 ETFWeight in the fund0.01%
- VTWOVanguard Russell 2000 Index FundWeight in the fund0.01%
- DFASDimensional U.S. Small Cap ETFWeight in the fund0.00%
- VHTVanguard Health Care Index FundWeight in the fund0.00%
- VXFVanguard Extended Market Index FundWeight in the fund0.00%
- VTIVanguard Total Stock Market Index FundWeight in the fund0.00%
- DFAUDimensional US Core Equity Market ETFWeight in the fund0.00%
12 of the 349 ETFs we track, not of every ETF on the market. The ten largest weights. Positions as each fund filed them in its latest N-PORT.
Institutional investors by quarter
Every manager that reports positions to the SEC (Form 13F), quarter by quarter: how many hold the stock, how many shares and dollars between them, and who entered, left, added or trimmed during the quarter.
- Managers
- Q3 2025: Managers 99
- Q4 2025: Managers 86
- Q1 2026: Managers 103
- Q2 2026: Managers 114
Institutional investors by quarter
The fund managers holding ZNTL, quarter by quarter, from Q2 2020 to Q2 2025, 21 more quarters
Part of Ploutos Investor, €9.99 a month
Sign in with a free account to see the last 12 quarters.
Q2 2026: 114 managers held 47.38M shares, worth $229M. During the quarter 34 opened a position, 23 closed one, 27 added and 32 trimmed.
The largest holders, Q2 2026
- 5AM Venture ManagementIn the quarter
- BlackRockIn the quarter+196%
- Squadron Capital ManagementIn the quarter+1.9%
- Two Sigma InvestmentsIn the quarter+2.3%
- Vanguard Capital ManagementIn the quarter+23%
- Acadian Asset ManagementIn the quarter-5.8%
- Citadel Advisors (Griffin)In the quarter+33%
- Renaissance TechnologiesIn the quarter-17%
- Opaleye ManagementIn the quarter
- Orbimed AdvisorsIn the quarter
| Manager | Shares | In the quarter | Value |
|---|---|---|---|
| 5AM Venture Management | 3.95M | $19M | |
| BlackRock | 3.75M | +196% | $18M |
| Squadron Capital Management | 3.70M | +1.9% | $18M |
| Two Sigma Investments | 3.02M | +2.3% | $15M |
| Vanguard Capital Management | 2.84M | +23% | $14M |
| Acadian Asset Management | 2.68M | -5.8% | $13M |
| Citadel Advisors (Griffin) | 2.30M | +33% | $11M |
| Renaissance Technologies | 1.61M | -17% | $7.8M |
| Opaleye Management | 1.41M | $6.9M | |
| Orbimed Advisors | 1.39M | $6.7M |
From the SEC's Form 13F data sets, Q3 2025 to Q2 2026: the long positions of every manager with more than $100 million under management, as filed up to 45 days after each quarter end. Short positions and options are not in them. Shares as reported each quarter, not adjusted for splits. The stock is matched by its CUSIP, through the SEC's fails-to-deliver files.
Pay against performance, the say-on-pay vote, buybacks by quarter and trading plans are read for S&P 500 companies only.
The full analysis
What do Zentalis Pharmaceuticals's filings show?
Who buys and sells is one part of Zentalis Pharmaceuticals's picture. The full Ploutos AI analysis reads everything the company has filed and shows what stands behind it, with a source for every figure.
- A fair value range built from the filings
- Earnings quality, debt and red flags
- Insider and institutional moves
- The case for and the case against
Have ZNTL's insiders bought or sold?
From May 27, 2026 to Oct 1, 2026 Zentalis Pharmaceuticals's insiders bought $15M and sold 0 of shares on the market. – of the sales were under set 10b5-1 plans.
Which well-known managers hold ZNTL?
5 of the managers we track held the shares on Sep 30, 2026. The largest position was Citadel Advisors (Griffin)'s, worth $12M.
Is every insider transaction a purchase or a sale?
No. Many are part of their pay: share awards, option exercises and shares the company keeps for the tax. Only code P is a purchase with their own money, and code S a sale on the market.
Related pages
The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.
The figures come from the company's SEC filings and the share price, and describe what it has reported. They are not a score or a fair value.